Loading...
XKRX003850
Market cap601mUSD
Dec 26, Last price  
10,450.00KRW
1D
2.15%
1Q
-5.00%
Jan 2017
13.32%
Name

Boryung Corp

Chart & Performance

D1W1MN
XKRX:003850 chart
P/E
21.82
P/S
1.02
EPS
478.82
Div Yield, %
0.75%
Shrs. gr., 5y
3.10%
Rev. gr., 5y
13.30%
Revenues
859.63b
+13.04%
197,500,614,000223,259,471,000267,844,294,000300,958,914,000308,005,546,820312,075,037,440327,278,733,560359,490,950,700401,350,239,840409,140,006,900422,721,051,680460,401,670,470524,268,670,100561,866,592,450627,279,390,050760,475,844,690859,625,585,760
Net income
40.20b
-4.04%
8,418,563,0005,205,610,0005,182,161,00013,648,778,0006,178,116,7309,401,047,02014,126,625,32021,590,563,67020,301,086,0305,614,105,35056,698,581,46020,306,902,10032,221,802,69026,856,199,16043,044,274,38041,894,431,74040,202,797,520
CFO
42.22b
+51.81%
20,223,089,00013,079,677,0003,593,431,00022,939,541,0009,185,915,50018,378,731,06028,527,119,2609,340,832,30017,114,340,7209,363,178,140-24,263,565,30038,913,967,70046,998,848,99044,740,976,18060,167,363,91027,814,064,61042,223,902,690
Dividend
Dec 27, 2023100 KRW/sh
Earnings
Jan 27, 2025

Profile

Boryung Corporation produces and sells pharmaceutical products in South Korea. The company offers cardiovascular products, anticancer products, gastrointestinal products, and API's. It also exports its products to approximately 50 countries on 6 continents, including Japan, China, the Southeast Asia, the Middle East, Europe, South America, and Africa. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is based in Seoul, South Korea.
URL
https://www.boryung.co.kr/en/
IPO date
Oct 24, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
859,625,586
13.04%
760,475,845
21.23%
627,279,390
11.64%
Cost of revenue
645,538,831
587,011,212
490,947,609
Unusual Expense (Income)
NOPBT
214,086,754
173,464,632
136,331,781
NOPBT Margin
24.90%
22.81%
21.73%
Operating Taxes
16,092,403
16,933,656
27,598,892
Tax Rate
7.52%
9.76%
20.24%
NOPAT
197,994,351
156,530,976
108,732,889
Net income
40,202,798
-4.04%
41,894,432
-2.67%
43,044,274
60.28%
Dividends
(6,586,571)
(6,588,571)
(4,511,097)
Dividend yield
0.84%
1.10%
0.49%
Proceeds from repurchase of equity
(185,671)
93,825,719
BB yield
0.03%
-10.20%
Debt
Debt current
51,633,442
113,697,450
26,273,257
Long-term debt
154,479,135
95,679,915
189,987,703
Deferred revenue
(9,744,416)
3,213,525
Other long-term liabilities
12,593,579
3,934,012
1,763,471
Net debt
51,420,347
64,056,406
8,044,645
Cash flow
Cash from operating activities
42,223,903
27,814,065
60,167,364
CAPEX
(15,020,194)
(122,995,419)
(59,317,461)
Cash from investing activities
(29,161,099)
(147,650,952)
(47,760,667)
Cash from financing activities
(12,645,813)
(14,649,025)
111,989,133
FCF
138,376,535
120,526,923
136,286,118
Balance
Cash
20,054,672
17,916,970
201,438,195
Long term investments
134,637,559
127,403,989
6,778,120
Excess cash
111,710,952
107,297,166
176,852,345
Stockholders' equity
377,430,344
483,869,021
440,028,595
Invested Capital
653,848,065
595,099,306
505,534,007
ROIC
31.71%
28.44%
21.36%
ROCE
27.95%
24.36%
19.86%
EV
Common stock shares outstanding
65,931
66,126
63,029
Price
11,890.00
31.24%
9,060.00
-37.95%
14,600.00
-6.21%
Market cap
783,921,659
30.85%
599,103,680
-34.90%
920,217,998
-0.50%
EV
835,844,951
663,659,251
928,713,209
EBITDA
258,473,824
211,108,822
168,405,969
EV/EBITDA
3.23
3.14
5.51
Interest
9,549,147
6,127,446
4,478,051
Interest/NOPBT
4.46%
3.53%
3.28%